AgenusAGEN
About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Employees: 316
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
575% more call options, than puts
Call options by funds: $398K | Put options by funds: $59K
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 85 [Q4 2024] → 87 (+2) [Q1 2025]
2.46% less ownership
Funds ownership: 35.97% [Q4 2024] → 33.51% (-2.46%) [Q1 2025]
12% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 25
45% less capital invested
Capital invested by funds: $23.1M [Q4 2024] → $12.8M (-$10.4M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Baird Colleen Kusy | 1%downside $6 | Neutral Maintained | 4 Jun 2025 |
HC Wainwright & Co. Emily Bodnar | 315%upside $25 | Buy Upgraded | 4 Jun 2025 |
Financial journalist opinion
Based on 5 articles about AGEN published over the past 30 days
